Nastech Partners With Merck On Phase I Obesity Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Nastech cites Merck’s demonstrated urgency to enter the class and its R&D capabilities as a reason to collaborate on the nasal spray agent earlier than planned and before it has completed Phase II trials. Merck would be primarily responsible for worldwide research, regulatory approvals, sales and marketing.